Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer

Nishimura,Reiki; Osako,Tomofumi; Nishiyama,Yasuyuki; Tashima,Rumiko; Nakano,Masahiro; Fujisue,Mamiko; Toyozumi,Yasuo; Arima,Nobuyuki

doi:10.3892/mco.2014.400

Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer

Authors:
- Reiki Nishimura
- Tomofumi Osako
- Yasuyuki Nishiyama
- Rumiko Tashima
- Masahiro Nakano
- Mamiko Fujisue
- Yasuo Toyozumi
- Nobuyuki Arima
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862-8505, Japan, Department of Surgery, Kumamoto City Hospital, Kumamoto 862-8505, Japan, Department of Pathology, Kumamoto City Hospital, Kumamoto 862-8505, Japan
Published online on: August 22, 2014 https://doi.org/10.3892/mco.2014.400
Pages: 1062-1068

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Ki-67 index value is a prognostic factor in primary breast cancer and is a proliferation marker that also distinguishes between luminal type A and type B breast cancer. Moreover, a change in Ki-67 index values due to treatment and recurrence is considered to be important in treating breast cancer. In this study, we investigated whether the baseline Ki-67 value in the primary tumor is useful as a prognostic factor following disease recurrence. Immunohistochemical analysis of the Ki-67 index was performed on 4,701 patients with primary breast cancer from 1987 until March, 2013. Among these patients, there were 666 consecutive cases exhibiting recurrence after primary surgery. The fraction of proliferating cells was based on a count of at least 500 tumor cells in the area including the hot spot. The Ki-67 values were divided into 3 groups, namely <20, ≥20 and ≥50%. The investigated items included estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), tumor size, nodal status for the primary tumor, recurrence site (soft tissue, bone and viscera) and disease‑free interval (DFI). The Cox's proportional hazard model was used to perform univariate and multivariate analyses of the factors associated with overall survival (OS) following recurrence. The median follow-up period was 65.9 months in the surviving group. The median Ki-67 value at baseline was 20% in all the cases and 27% in the recurrent cases. The Ki-67 values were low (24%) in patients with bone metastasis and significantly higher in patients with liver or brain metastasis (38 and 55%, respectively). Moreover, DFI was found to be inversely correlated with the Ki-67 values. Univariate analysis was performed to identify the prognostic factors for OS after recurrence. The significant factors included tumor size, lymph node status, ER, PgR, DFI, recurrence site and Ki-67 index value. Among these factors, a multivariate analysis identified the Ki-67 index value in the primary tumor as an independent significant factor, particularly in luminal type tumors. The Ki-67 index value in the primary tumor was a significant prognostic factor for OS after disease recurrence. It is, therefore, important to take the Ki-67 index value into consideration for the treatment and follow-up of breast cancer patients.

View Figures

View References

1	Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 339:974–984. 1998. View Article : Google Scholar
3	Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D and Piccart MJ: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
4	Stuart-Harris R, Caldas C, Pinder SE and Pharoah P: Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
5	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
6	Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
7	Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M and Nielsen TO; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. J Natl Cancer Inst. 105:1897–1906. 2013. View Article : Google Scholar : PubMed/NCBI
8	Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y and Arima N: Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 1:747–754. 2010. View Article : Google Scholar : PubMed/NCBI
9	de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI
10	Jonat W and Arnold N: Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 22:500–502. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
12	Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D and Pusztai L: Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 135:619–627. 2012. View Article : Google Scholar
13	Kai K, Nishimura R, Arima N, Miyayama H and Iwase H: p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol. 11:426–433. 2006. View Article : Google Scholar : PubMed/NCBI
14	Goldhirsch A, Glick JH, Gelber RD and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 90:1601–1608. 1998. View Article : Google Scholar : PubMed/NCBI
15	Taktak AF, Eleuteri A, Lake SP and Fisher AC: A web-based tool for the assessment of discrimination and calibration properties of prognostic models. Comput Biol Med. 38:785–791. 2008. View Article : Google Scholar : PubMed/NCBI
16	Harrell FE Jr, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA. 247:2543–2546. 1982. View Article : Google Scholar : PubMed/NCBI
17	Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA and Hayes DF; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
18	Reyal F, Hajage D, Savignoni A, et al: Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One. 8:e559012013. View Article : Google Scholar : PubMed/NCBI
19	Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y and Akiyama F: Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer. Mar 12–2013.(Epub ahead of print).
20	Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y and Arima N: Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 9:131–137. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y and Arima N: Evaluation of factors related to late recurrence - later than 10 years after the initial treatment - in primary breast cancer. Oncology. 85:100–110. 2013.
22	Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL and Boyages J: The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol. 67:222–228. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E, Marquez A, Alvarez M, Sanchez-Muñoz A, Perez-Rivas L and Alba E: Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res. 15:R982013. View Article : Google Scholar : PubMed/NCBI
24	Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L and Amadori D: Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology. 84:150–157. 2013. View Article : Google Scholar